Last reviewed · How we verify
NCT04696848
The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors
Phase 1, PHASE2 trial testing CKD-516 plus Durvalumab in Colorectal Cancer in 25 participants. Terminated before completion.
9 March 2023
Quick facts
| Lead sponsor | Tae Won Kim |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 24 February 2021 |
| Primary completion | 9 March 2023 |
| Estimated completion | 9 March 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- CKD-516 plus Durvalumab — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Tae Won Kim — full company profile →
Who can join
20 and older, any sex, with Colorectal Cancer or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, open-label, nonrandomized, Phase 1b, dose-escalation study designed to determine maximum tolerated dose (MTD) of CKD-516 in combination with durvalumab and evaluate the safety and tolerability profile, efficacy of CKD-516 and durvalumab treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting macrophages: a novel treatment strategy in solid tumors.
Liu M, Liu L, Song Y, Li W, et al · · 2022 · cited 52× · PMID 36510315 · DOI 10.1186/s12967-022-03813-w
Verify or expand the search:
- PubMed search for NCT04696848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Tae Won Kim trials
Trials by the same sponsor.
- NCT04954339 — DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04696848 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tae Won Kim
- Last refreshed: 21 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing